Ardelyx Inc (ARDX)
$5.28
2.29 (30.25%)
ARDX Stock Quote Delayed 30 Minutes
3 Stocks Under $10 With the Potential to Make You a Millionaire
Looking for volume plays? Here are three stocks under $10 that might just drive your earnings to millions in the next few years.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
544.47M
PE Ratio
-18.21
EPS
-0.29
Volume (Avg. Vol.)
22.67M
Day's Range
$5.07 - $6.47
52-Week Range
$3.16 - $10.13
Dividend & Yield
N/A (N/A)
ARDX Stock Predictions, Articles, and Ardelyx Inc News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!
ARDX Stock Earnings: Ardelyx Beats EPS, Beats Revenue for Q1 2024
ARDX stock results show that Ardelyx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug
ARDX stock is rallying after the U.S. Food and Drug Administration (FDA) approved Ardelyx's kidney disease treatment.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
